ACE2 and COVID-19: Treatment with ACEIs and ARBs arguably, though without reproducible evidence, should increase ACE2 levels as a result of redirecting Ang 1 and Ang II to Ang 1–9 and Ang1–7, respectively, and should thus prove protective against COVID-19.